- Home
- LODE vs CHRS Comparison
LODE vs CHRS Comparison
Compare LODE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LODE
- CHRS
- Stock Information
- Founded
- LODE 2008
- CHRS 2010
- Country
- LODE United States
- CHRS United States
- Employees
- LODE N/A
- CHRS N/A
- Industry
- LODE Major Chemicals
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LODE Industrials
- CHRS Health Care
- Exchange
- LODE Nasdaq
- CHRS Nasdaq
- Market Cap
- LODE 53.0M
- CHRS 84.2M
- IPO Year
- LODE N/A
- CHRS 2014
- Fundamental
- Price
- LODE $3.63
- CHRS $0.85
- Analyst Decision
- LODE Buy
- CHRS Buy
- Analyst Count
- LODE 1
- CHRS 3
- Target Price
- LODE $26.00
- CHRS $4.68
- AVG Volume (30 Days)
- LODE 463.6K
- CHRS 1.3M
- Earning Date
- LODE 08-07-2025
- CHRS 08-07-2025
- Dividend Yield
- LODE N/A
- CHRS N/A
- EPS Growth
- LODE N/A
- CHRS N/A
- EPS
- LODE N/A
- CHRS N/A
- Revenue
- LODE $3,376,027.00
- CHRS $272,251,000.00
- Revenue This Year
- LODE $33.58
- CHRS N/A
- Revenue Next Year
- LODE N/A
- CHRS $99.43
- P/E Ratio
- LODE N/A
- CHRS N/A
- Revenue Growth
- LODE 102.20
- CHRS 19.87
- 52 Week Low
- LODE $1.26
- CHRS $0.66
- 52 Week High
- LODE $10.10
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- LODE 52.37
- CHRS 53.52
- Support Level
- LODE $3.52
- CHRS $0.73
- Resistance Level
- LODE $3.74
- CHRS $0.96
- Average True Range (ATR)
- LODE 0.21
- CHRS 0.05
- MACD
- LODE -0.05
- CHRS 0.02
- Stochastic Oscillator
- LODE 43.14
- CHRS 53.92
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.